NPM::ALK transcript levels and anti-ALK autoantibody titers as biomarkers for outcome in pediatric ALK plus anaplastic large cell lymphoma treated with brentuximab vedotin or crizotinib in combination with chemotherapy: COG ANHL12P1 Meeting Abstract
| Authors: | Forlenza, C. J.; Hoogstra, D.; Barkauskas, D.; Saguilig, L.; Turner, S. D.; Prokoph, N.; Pucci, P.; Hare, L.; Jahangiri, L.; Wu, R.; Elenitoba-Johnson, K. S. J.; Lowe, E. J.; Lim, M. S. |
| Abstract Title: | NPM::ALK transcript levels and anti-ALK autoantibody titers as biomarkers for outcome in pediatric ALK plus anaplastic large cell lymphoma treated with brentuximab vedotin or crizotinib in combination with chemotherapy: COG ANHL12P1 |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 1582 |
| End Page: | 1582 |
| Language: | English |
| ACCESSION: | WOS:001410640300036 |
| DOI: | 10.1182/blood-2024-201677 |
| PROVIDER: | wos |
| Notes: | Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work